In addition, as WT1 is one of the HIF downstream oncogene targets, it will be mandatory to monitor the development and progression of WT1-mediated cancers including ovarian, breast, lung, uterine, colon cancers, pleural mesothelioma and hematologic malignancies. Here, WT1 is linked to hematologic disorder.